Experimental neurology, 2010-06, Vol.223 (2), p.334-346
2010
Details
- Autor(en) / Beteiligte
- Titel
- Biological markers of amyloid β-related mechanisms in Alzheimer's disease
- Ist Teil von
- Experimental neurology, 2010-06, Vol.223 (2), p.334-346
- Ort / Verlag
- United States: Elsevier Inc
- Erscheinungsjahr
- 2010
- Link zum Volltext
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Recent research progress has given detailed knowledge on the molecular pathogenesis of Alzheimer's disease (AD), which has been translated into an intense, ongoing development of disease-modifying treatments. Most new drug candidates are targeted on inhibiting amyloid β (Aβ) production and aggregation. In drug development, it is important to co-develop biomarkers for Aβ-related mechanisms to enable early diagnosis and patient stratification in clinical trials, and to serve as tools to identify and monitor the biochemical effect of the drug directly in patients. Biomarkers are also requested by regulatory authorities to serve as safety measurements. Molecular aberrations in the AD brain are reflected in the cerebrospinal fluid (CSF). Core CSF biomarkers include Aβ isoforms (Aβ40/Aβ42), soluble APP isoforms, Aβ oligomers and β-site APP-cleaving enzyme 1 (BACE1). This article reviews recent research advances on core candidate CSF and plasma Aβ-related biomarkers, and gives a conceptual review on how to implement biomarkers in clinical trials in AD.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0014-4886, 1090-2430eISSN: 1090-2430DOI: 10.1016/j.expneurol.2009.09.024Titel-ID: cdi_swepub_primary_oai_gup_ub_gu_se_126840
- Format
- –
- Schlagworte
- Alzheimer Disease, Alzheimer Disease - drug therapy, Alzheimer Disease - metabolism, Alzheimer Disease - pathology, Alzheimer's disease (AD), Alzheimer's Disease Neuroimaging Initiative (ADNI), Amyloid beta-Peptides - metabolism, Amyloid beta-Protein, Amyloid precursor protein (APP), Amyloid β-peptide (Aβ), Biochemical markers, Biological Markers, Biomarkers, Biomarkers - metabolism, Brain, Brain - metabolism, Brain - pathology, Cerebrospinal fluid (CSF), Clinical Trials as Topic, Clinical Trials as Topic - methods, Diagnosis, Drug development, drug therapy, European Medicines Agency (EMEA), Humans, Mechanism of action, metabolism, methods, Mild cognitive impairment (MCI), Neurochemistry, Oligomers, pathology, Plasma, Pre-clinical, Prediction, Presymptomatic, Psychiatry, Psykiatri, Stratification, US Food and Drug Administration (FDA), β-Site APP-cleaving enzyme 1 (BACE1)